- 商品介绍
- 规格参数
- 包装参数
Biochem/physiol Actions
LY2090314 can decrease the development of human MYCN amplified and non-amplified neuroblastoma (NB) cell lines in vitro. It has the ability to prevent the multiplication, colony formation and cell confluency of neuroblastoma.
LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) currently in clinical trials for cancer therapy. LY2090314 has IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3).
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | yellow to orange |
| solubility | DMSO: 10 mg/mL, clear |
| storage temp. | −20°C |
| SMILES string | O=C(N1CCCCC1)N(C2)CCN3C4=C2C=C(F)C=C4C(C5=C(C6=CN=C7N6C=CC=C7)C(NC5=O)=O)=C3 |
| InChI | 1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37) |
| InChI key | HRJWTAWVFDCTGO-UHFFFAOYSA-N |
| Gene Information | human ... GSK3A(2931), GSK3B(2932) |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
-
询价
-
询价
-
询价
-
询价
-
询价
-
询价
-
¥ 4968.78
-
¥ 5725.45
-
¥ 1301.36
-
¥ 1196.14
-
¥ 5061.38
-
¥ 2132.12
-
¥ 9909.51
-
¥ 2888.88
-
¥ 5990.26
-
¥ 70526.15
-
¥ 65710.50
-
¥ 41825.84
-
¥ 15894.19
-
询价
微信小程序
7X24小时在线咨询